Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 20/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL826735 | 0.99 | GCK (0.56) | GCK | |
| SCHEMBL4460293 | 0.98 | GCK (0.55) | GCK | |
| SCHEMBL4471625 | 0.94 | GCK (0.54) | GCK | |
| SCHEMBL926396 | 0.90 | GCK (0.61) | GCK | |
| SCHEMBL4464032 | 0.90 | GCK (0.58) | GCK | |
| SCHEMBL4456575 | 0.90 | GCK (0.58) | GCK | |
| SCHEMBL4470708 | 0.90 | GCK (0.53) | GCK | |
| SCHEMBL15060304 | 0.89 | GCK (0.56) | GCK | |
| SCHEMBL14199097 | 0.89 | GCK (0.52) | GCK | |
| SCHEMBL671857 | 0.88 | GCK (0.57) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2077266-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-08 | — | — | EP | claimed |
| US-20080090799-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING EFFECT | MSD K.K. (JP) | 2008-04-17 | — | — | US | claimed |
| US-8338460-B2 | 3-({4-[2-(dimethylamino)ethoxy]phenyl}thio)-N-(3-methyl-1,2,4-thiadiazol-5-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)thio]pyridine-2-carboxamide; glucokinase activator; antidiabetic, obesity | MSD K. K. (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8338460-B2 | 3-({4-[2-(dimethylamino)ethoxy]phenyl}thio)-N-(3-methyl-1,2,4-thiadiazol-5-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)thio]pyridine-2-carboxamide; glucokinase activator; antidiabetic, obesity | MSD K. K. (JP) | 2012-12-25 | — | — | US | disclosed |
| US-8338460-B2 | 3-({4-[2-(dimethylamino)ethoxy]phenyl}thio)-N-(3-methyl-1,2,4-thiadiazol-5-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)thio]pyridine-2-carboxamide; glucokinase activator; antidiabetic, obesity | MSD K. K. (JP) | 2012-12-25 | — | — | US | disclosed |
| EP-2077266-B1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING ACTIVITY | MSD KK (JP) | 2012-07-25 | — | — | EP | disclosed |
| EP-2077266-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-08 | — | — | EP | disclosed |
| EP-2077266-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-08 | — | — | EP | disclosed |
| US-20080090799-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING EFFECT | MSD K.K. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20080090799-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING EFFECT | MSD K.K. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20080090799-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING EFFECT | MSD K.K. (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090799-A1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE HAVING GK-ACTIVATING EFFECT | GCKR, GCK, GPR119 | GCK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.